RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers : the RE-RAFFLE study
© 2024. The Author(s)..
Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged with a second RAF inhibitor, either as monotherapy or in combination with other therapies, after prior therapy with a first RAF inhibitor. This retrospective observational study results showed that rechallenging with RAFi(s) led to an overall response rate of 18.1% [PR in thyroid (1 anaplastic; 3 papillary), 1 ovarian, 2 melanoma, 1 cholangiocarcinoma, and 1 anaplastic astrocytoma]. The clinical benefit rate was 54.5%; more than 30% of patients had durable responses with PR and SD lasting > 6 months. The median progression-free survival on therapy with second RAF inhibitor in the rechallenge setting either as monotherapy or combination was shorter at 2.7 months (0.9-30.1 m) compared to 8.6 months (6.5-11.5 m) with RAF-1i. However, the median PFS with RAF-2i responders (PFS-2) improved at 12.8 months compared to 11.4 months with RAF-1i responders. The median OS from retreatment with RAF-2i was 15.5 months (11.1-30.8 m). Further prospective studies are needed to validate these results and expand targeted therapy options for RAF-aberrant cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Molecular cancer - 23(2024), 1 vom: 26. März, Seite 64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nelson, Blessie Elizabeth [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAF inhibitors |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 03.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12943-024-01982-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37022003X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37022003X | ||
| 003 | DE-627 | ||
| 005 | 20240404235203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12943-024-01982-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM37022003X | ||
| 035 | |a (NLM)38532456 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nelson, Blessie Elizabeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers |b the RE-RAFFLE study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged with a second RAF inhibitor, either as monotherapy or in combination with other therapies, after prior therapy with a first RAF inhibitor. This retrospective observational study results showed that rechallenging with RAFi(s) led to an overall response rate of 18.1% [PR in thyroid (1 anaplastic; 3 papillary), 1 ovarian, 2 melanoma, 1 cholangiocarcinoma, and 1 anaplastic astrocytoma]. The clinical benefit rate was 54.5%; more than 30% of patients had durable responses with PR and SD lasting > 6 months. The median progression-free survival on therapy with second RAF inhibitor in the rechallenge setting either as monotherapy or combination was shorter at 2.7 months (0.9-30.1 m) compared to 8.6 months (6.5-11.5 m) with RAF-1i. However, the median PFS with RAF-2i responders (PFS-2) improved at 12.8 months compared to 11.4 months with RAF-1i responders. The median OS from retreatment with RAF-2i was 15.5 months (11.1-30.8 m). Further prospective studies are needed to validate these results and expand targeted therapy options for RAF-aberrant cancers | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a BRAF inhibitors | |
| 650 | 4 | |a BRAF-altered solid tumors | |
| 650 | 4 | |a RAF pathway | |
| 650 | 4 | |a Rechallenge | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Roszik, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Jibran |e verfasserin |4 aut | |
| 700 | 1 | |a Barretto, Carmelia Maria Noia |e verfasserin |4 aut | |
| 700 | 1 | |a Nardo, Mirella |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Erick |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Amber M |e verfasserin |4 aut | |
| 700 | 1 | |a Piha-Paul, Sarina A |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Isabella C Glitza |e verfasserin |4 aut | |
| 700 | 1 | |a Weathers, Shiao-Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Cabanillas, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Javle, Milind |e verfasserin |4 aut | |
| 700 | 1 | |a Meric-Bernstam, Funda |e verfasserin |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer |d 2002 |g 23(2024), 1 vom: 26. März, Seite 64 |w (DE-627)NLM120915979 |x 1476-4598 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:26 |g month:03 |g pages:64 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12943-024-01982-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 26 |c 03 |h 64 | ||